| 101 |
NCT02097056 |
Completed
Has Results |
Safety and Efficacy of Donepezil HCl 23 mg in Patients With Moderate to Severe Alzheimer's Disease |
|
|
Interventional |
Phase 4 |
- Eisai Korea Inc.
- Eisai Inc.
|
Industry |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Overall Summary of Adverse Events (AEs)
- Change From Baseline in the Mini-Mental State Examination (MMSE) Score
- Change From Baseline in the Neuropsychiatric Inventory Questionnaire (NPI-Q) Severity and Distress Total Scores
|
171 |
All |
45 Years to 90 Years (Adult, Senior) |
NCT02097056 |
ART-M082-401 |
SAVE |
February 2014 |
May 2015 |
May 2015 |
March 26, 2014 |
June 27, 2016 |
June 27, 2016 |
- Chungju, Chungcheongbuk-do, Korea, Republic of
- Ansan, Gyeonggi-do, Korea, Republic of
- Buchoen, Gyeonggi-do, Korea, Republic of
- (and 10 more...)
|
| 102 |
NCT01689233 |
Completed |
Safety and Efficacy Study Evaluating TRx0237 in Subjects With Mild Alzheimer's Disease |
|
- Drug: TRx0237 200 mg/day
- Drug: Placebo
|
Interventional |
Phase 3 |
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
|
- Change from Baseline in Alzheimer's Disease Assessment Scale - Cognitive Subscale (ADAS-cog11)
- Change from Baseline in Alzheimer's Disease Cooperative Study - Activities of Daily Living (ADCS-ADL23)
- Number of study participants who tolerate oral doses of TRx0237 as determined by safety parameter changes
- (and 5 more...)
|
800 |
All |
up to 89 Years (Child, Adult, Senior) |
NCT01689233 |
TRx-237-005 |
|
October 2012 |
May 2016 |
May 2016 |
September 21, 2012 |
March 14, 2018 |
|
- Xenoscience, Inc / 21st Century Neurology
Phoenix, Arizona, United States - NoesisPharma Clinical Trials
Phoenix, Arizona, United States - CITrials
Bellflower, California, United States - (and 92 more...)
|
| 103 |
NCT00744978 |
Completed
Has Results |
Evaluation of the Efficacy of Varenicline on Cognition, Safety, Tolerability and Pharmacokinetics in Subjects With Mild-to-Moderate Alzheimer's Disease |
|
- Drug: Varenicline
- Drug: Placebo
|
Interventional |
Phase 2 |
|
Industry |
- Allocation: Randomized
- Intervention Model: Crossover Assignment
- Masking: Triple (Participant, Care Provider, Investigator)
- Primary Purpose: Treatment
|
- Alzheimer's Disease Assessment Scale-Cognitive Subscale 75 (ADAS-Cog 75) at Week 6
- Alzheimer's Disease Assessment Scale-Cognitive Subscale 75 (ADAS-Cog 75) at Week 3
- Alzheimer's Disease Assessment Scale-Cognitive Subscale 70 (ADAS-Cog 70) at Week 3
- (and 19 more...)
|
66 |
All |
55 Years to 85 Years (Adult, Senior) |
NCT00744978 |
A3051101 |
|
July 2009 |
November 2010 |
November 2010 |
September 1, 2008 |
November 22, 2011 |
November 22, 2011 |
- Pfizer Investigational Site
Seongnam, Gyunggido, Korea, Republic of - Pfizer Investigational Site
Busan, Korea, Republic of - Pfizer Investigational Site
Daegu, Korea, Republic of - (and 5 more...)
|
| 104 |
NCT00423085 |
Completed
Has Results |
Efficacy and Safety of Rivastigmine Transdermal Patch in Patients With Mild to Moderate Alzheimer's Disease |
|
- Drug: Rivastigmine transdermal patch
- Drug: Placebo
|
Interventional |
Phase 3 |
- Novartis Pharmaceuticals
- Ono Pharmaceutical Co. Ltd
- Novartis
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Triple (Participant, Care Provider, Investigator)
- Primary Purpose: Treatment
|
- Change From Baseline in the Alzheimer's Disease Assessment Scale - Japan Cognitive Subscale (ADAS-J Cog)
- Overall Clinical Rating of Change From Baseline to Week 24 Measured by the Clinician's Interview-Based Impression of Change Plus - Japan (CIBIC Plus-J)
- Change From Baseline in CIBIC Plus-J Score Disability Assessment for Dementia (DAD)
- (and 6 more...)
|
859 |
All |
50 Years to 85 Years (Adult, Senior) |
NCT00423085 |
CENA713D1301
CENA713D1301E1 |
|
January 2007 |
March 2009 |
April 2010 |
January 17, 2007 |
February 10, 2014 |
May 25, 2011 |
- Novartis Investigative Site
Hokkaido region, Hokkaido, Japan
|
| 105 |
NCT01322373 |
Unknown † |
A Study of Alzheimer's Disease Using Magnetoencephalography (MEG) and the Synchronous Neural Interaction™ Test |
|
|
Observational |
|
|
Industry |
- Observational Model: Case Control
- Time Perspective: Prospective
|
- Identification and characterization of patterns of correlated brain activity measured by MEG and the Orasi SNI test that differ consistently between HC and AD subjects.
|
120 |
All |
20 Years to 92 Years (Adult, Senior) |
NCT01322373 |
ADG 11-01 |
|
March 2011 |
August 2011 |
August 2011 |
March 24, 2011 |
March 24, 2011 |
|
- Noran Neurological Clinic
Minneapolis, Minnesota, United States - Noran Neurology Clinic
Plymouth, Minnesota, United States
|
| 106 |
NCT01384344 |
Completed |
Ecological Assessment of Apathy in Alzheimer's Disease and in Control Subjects: Video Recognition and Actigraphy |
|
|
Interventional |
Not Applicable |
- Centre Hospitalier Universitaire de Nice
|
Other |
- Allocation: Non-Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Basic Science
|
- stride and speed walking
- For comparison between Alzheimer disease patients with (n=20) or without apathy, we use again stride and speed walking
- For reproducibility, we use stride and speed walking
- (and 2 more...)
|
82 |
All |
65 Years and older (Adult, Senior) |
NCT01384344 |
11-PP-03 |
|
June 2011 |
December 2011 |
June 2012 |
June 29, 2011 |
December 18, 2012 |
|
- Hôpital de Cimiez
Nice, France
|
| 107 |
NCT00381381 |
Completed
Has Results |
The Clinical Response of Choline Acetyltransferase and Apolipoprotein Epsilon Gene Polymorphisms to Donepezil in Alzheimer's Disease |
|
|
Interventional |
Phase 4 |
- Eisai Korea Inc.
- Eisai Inc.
|
Industry |
- Allocation: Non-Randomized
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- CERAD-K (the Korean Version of the Consortium to Establish a Registry for Alzheimer's Disease)
- CERAD-K
- Neuropsychiatry Inventory (NPI)
- GDS-K (Geriatric Depression Scale-Korean) Score After Treatment
|
199 |
All |
60 Years to 90 Years (Adult, Senior) |
NCT00381381 |
EKI-6-004 |
|
May 2006 |
August 2008 |
December 2008 |
September 27, 2006 |
August 31, 2012 |
July 27, 2012 |
- Seoul National University Bundang Hospital
Bundang, Korea, Republic of - Hallym University Medical Center
Changwon, Korea, Republic of - Kangwon National University Hospital
Chuncheon, Korea, Republic of - (and 12 more...)
|
| 108 |
NCT02772185 |
Recruiting |
Neurostimulation and Cognitive Intervention in Alzheimer's Disease |
|
- Device: active tDCS
- Device: sham tDCS
- Behavioral: real CT
- Behavioral: placebo CT
|
Interventional |
Phase 2
Phase 3 |
- Federal University of Paraíba
|
Other |
- Allocation: Randomized
- Intervention Model: Factorial Assignment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
|
- Change in cognitive function assessed on the Alzheimer's Disease Assessment Scale-cognitive subscale (ADAS-Cog)
- Change in cognitive ability assessed on the Wechsler Adult Intelligence Scale
- Change in visuo-spatial working memory assessed on the Corsi block task
- (and 10 more...)
|
60 |
All |
60 Years to 90 Years (Adult, Senior) |
NCT02772185 |
NeuroAD |
NeuroAD |
May 2016 |
May 2018 |
May 2019 |
May 13, 2016 |
May 13, 2016 |
|
- Suellen Andrade
João Pessoa, PB, Brazil
|
| 109 |
NCT02220738 |
Terminated |
Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of ABT-957 in Subjects With Mild-to-Moderate Alzheimer's Disease on Stable Doses of Acetylcholinesterase Inhibitors |
|
- Drug: ABT-957
- Other: Placebo for ABT-957
|
Interventional |
Phase 1 |
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
|
- Pharmacokinetic evaluation of the two ABT-957 diastereomers
- Number of subjects with adverse events
|
19 |
All |
55 Years to 90 Years (Adult, Senior) |
NCT02220738 |
M13-334 |
|
September 2014 |
March 2016 |
March 2016 |
August 20, 2014 |
June 16, 2016 |
|
- Site Reference ID/Investigator# 129545
Glendale, California, United States - Site Reference ID/Investigator# 129435
Orlando, Florida, United States - Site Reference ID/Investigator# 129641
New York, New York, United States - Site Reference ID/Investigator# 144825
Salt Lake City, Utah, United States
|
| 110 |
NCT02537626 |
Not yet recruiting |
An Evaluation of Low Level Laser Light Therapy on Improving the Symptoms of Alzheimer's Disease |
|
- Device: Erchonia ALS Laser
- Device: Placebo Laser
|
Interventional |
Not Applicable |
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
|
- Alzheimer's Disease Assessment Scale-Cognitive Subscale (ADAS-Cog) Score
- Alzheimer's Disease Co-Operative Study-Activities of Daily Living Inventory (ADCS-ADL)
- Mini Mental State Examination (MMSE)
- Study Partner Satisfaction With Overall Outcome Rating
|
60 |
All |
50 Years to 85 Years (Adult, Senior) |
NCT02537626 |
EC_AD_001 |
|
February 15, 2018 |
December 15, 2018 |
December 15, 2018 |
September 1, 2015 |
January 19, 2018 |
|
- Pruebas Clinicas
Zapopan, Jalisco, Mexico - Neocemod
La Plazuela, Pocitos AGS, Mexico
|
| 111 |
NCT01058941 |
Completed
Has Results |
Lipoic Acid and Omega-3 Fatty Acids for Alzheimer's Disease |
|
- Drug: Lipoic acid and fish oil concentrate
- Drug: Placebo
|
Interventional |
Phase 1
Phase 2 |
- Oregon Health and Science University
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
|
- Change From Baseline in Activities of Daily Living (ADL) at 18 Months
- Change From Baseline in Alzheimer's Disease Assessment Scale - Cognitive Subscale (ADAS-cog) at 18 Months
|
67 |
All |
55 Years and older (Adult, Senior) |
NCT01058941 |
R01AG033613-01A1 |
|
September 2010 |
December 2014 |
December 2014 |
January 29, 2010 |
April 13, 2017 |
April 13, 2017 |
- Oregon Health & Science University
Portland, Oregon, United States
|
| 112 |
NCT01428453 |
Completed |
A Phase 2a Study to Evaluate the Effect of Rilapladib (SB-659032) in Alzheimer's Disease |
|
- Drug: 250mg rilapladib
- Drug: placebo
|
Interventional |
Phase 2 |
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Triple (Participant, Care Provider, Investigator)
- Primary Purpose: Treatment
|
- Change from baseline in CSF Abeta42, Abeta40, Abeta42/ Abeta40 ratio
- Change from baseline in CSF tau and P-tau
- Change from baseline in working memory/executive function composite score
- (and 6 more...)
|
124 |
All |
50 Years to 80 Years (Adult, Senior) |
NCT01428453 |
114458 |
|
October 2011 |
February 2013 |
February 2013 |
September 5, 2011 |
May 13, 2015 |
|
- GSK Investigational Site
Sofia, Bulgaria - GSK Investigational Site
Sofia, Bulgaria - GSK Investigational Site
Toronto, Ontario, Canada - (and 27 more...)
|
| 113 |
NCT03288363 |
Recruiting |
Transcranial Direct Current Stimulation and Early Alzheimer's Disease (tDCS-AD) |
|
|
Interventional |
Not Applicable |
- Benjamin CALVET
- Centre Hospitalier Esquirol
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
|
- Comparing between the active tDCS group with the placebo tDCS group, the cognitive subscale of the Alzheimer's Disease Assessment Scale (ADAS-Cog) score, 12 weeks after the start of the course, in subjects with early Alzheimer's disease
|
80 |
All |
18 Years and older (Adult, Senior) |
NCT03288363 |
2016-A01527-44 |
tDCS-AD |
June 6, 2017 |
June 6, 2019 |
December 6, 2019 |
September 20, 2017 |
April 5, 2018 |
|
- Centre Hospitalier Esquirol
Limoges, France
|
| 114 |
NCT00708552 |
Completed
Has Results |
Study of SB-742457 or Donepezil Versus Placebo in Subjects With Mild-to-moderate Alzheimer's Disease |
|
- Drug: SB-742457
- Drug: Donepezil
- Drug: Placebo
|
Interventional |
Phase 2 |
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Double (Participant, Investigator)
- Primary Purpose: Treatment
|
- Change From Baseline in Alzheimer's Disease Assessment Scale - Cognitive Subscale (ADAS-Cog) Total Score at Week 24
- Clinician's Interview-Based Impression of Change - Plus (CIBIC+) Score at Week 24
- Change From Baseline in Repeatable Battery for the Assessment of Neuropsychological Status (RBANS) Total Score at Week 24
- (and 34 more...)
|
576 |
All |
50 Years to 85 Years (Adult, Senior) |
NCT00708552 |
AZ3110865 |
|
July 4, 2008 |
March 1, 2010 |
March 9, 2010 |
July 2, 2008 |
March 12, 2018 |
February 12, 2018 |
- GSK Investigational Site
Shumen, Bulgaria - GSK Investigational Site
Sofia, Bulgaria - GSK Investigational Site
Sofia, Bulgaria - (and 69 more...)
|
| 115 |
NCT01428362 |
Completed |
VI-1121 for the Treatment Alzheimer's Disease |
|
- Drug: VI-1121
- Drug: Placebo
|
Interventional |
Phase 2 |
|
Industry |
- Allocation: Randomized
- Intervention Model: Crossover Assignment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
|
- The primary efficacy variable is the change in Alzheimer's Disease Assessment-Cognitive Subscale (ADAS-Cog) score from baseline to Week 12 of each treatment period.
- The secondary efficacy endpoint is the mean change in Mini-Mental State Examination (MMSE) score from baseline to Week 12 of each treatment period.
- Percentage of subjects who achieve 3-point improvement in ADAS-Cog score from baseline to Week 12 of each treatment period.
- (and 2 more...)
|
61 |
All |
60 Years to 85 Years (Adult, Senior) |
NCT01428362 |
AD-201 |
AD-201 |
August 2011 |
August 2013 |
August 2013 |
September 5, 2011 |
December 11, 2013 |
|
- San Francisco, California, United States
- Santa Monica, California, United States
- Sunrise, Florida, United States
- (and 8 more...)
|
| 116 |
NCT02839187 |
Completed |
Neuro Imaging and Multimodal Alzheimer's Disease |
|
|
Interventional |
Not Applicable |
- University Hospital, Toulouse
|
Other |
- Allocation: Non-Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Basic Science
|
- fixing the AV-45 during PET
- Deposition of amyloid protein
- Standard Cognitive function
- Specific memory evaluation
|
59 |
All |
60 Years to 85 Years (Adult, Senior) |
NCT02839187 |
07 306 02 |
NIMAD |
June 2010 |
May 2012 |
May 2012 |
July 20, 2016 |
May 11, 2017 |
|
- University Hospital of Toulouse
Toulouse, France
|
| 117 |
NCT01782742 |
Completed
Has Results |
Bexarotene Amyloid Treatment for Alzheimer's Disease |
|
- Drug: Bexarotene
- Drug: Placebo
|
Interventional |
Phase 2 |
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Double (Participant, Investigator)
- Primary Purpose: Treatment
|
- Drug-Placebo Difference in Change From Baseline to Week 4 in the Composite Amyloid Burden of the Brain
- Primary Outcome by Genotype (ALL SUBJECTS)
- Primary Outcome by Genotype (NON ApoE4 CARRIERS)
- (and 12 more...)
|
20 |
All |
50 Years to 90 Years (Adult, Senior) |
NCT01782742 |
CCF-IRB 12-783 |
BEAT-AD |
February 2013 |
August 2014 |
December 2014 |
February 4, 2013 |
February 12, 2016 |
February 12, 2016 |
- Cleveland Clinic Lou Ruvo Center for Brain Health
Las Vegas, Nevada, United States
|
| 118 |
NCT02600130 |
Recruiting |
Allogeneic Human Mesenchymal Stem Cell Infusion Versus Placebo in Patients With Alzheimer's Disease |
|
- Biological: Longeveron Mesenchymal Stem Cells
- Biological: Placebo
|
Interventional |
Phase 1 |
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
|
- To demonstrate the safety of LMSCs administered to subjects with Alzheimer's disease.
- Preliminary efficacy will be determined by examining for changes in AD status and rate decline as assessed by the following.
|
30 |
All |
50 Years to 80 Years (Adult, Senior) |
NCT02600130 |
00-0000-01 |
|
August 2016 |
August 2018 |
October 2019 |
November 9, 2015 |
April 23, 2018 |
|
- Brain Matters Research
Delray Beach, Florida, United States - University of Miami Miller School of Medicine
Miami, Florida, United States
|
| 119 |
NCT01399125 |
Completed
Has Results |
A 24-Week Efficacy, Safety and Tolerability of Rivastigmine Patch Study in Patients With Probable Alzheimer's Disease |
|
- Drug: Rivastigmine Patch
- Drug: Rivastigmine Capsules
- Drug: Placebo to Rivastigmine patch
- Drug: Placebo to Rivastigmine capsules
|
Interventional |
Phase 3 |
- Novartis Pharmaceuticals
- Novartis
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
|
- Change From Baseline on Cognition, Assessed by the Alzheimer's Disease Assessment Scale-Cognitive (ADAS-Cog)
- Change From Baseline in Global Functioning, Assessed by the Alzheimer's Disease Assessment Scale Clinical Impression of Change (ADCS-CGIC)
- Change From Baseline in Alzheimer's Disease Cooperative Study - Activities of Daily Living (ADCS-ADL) Total Score
- (and 2 more...)
|
501 |
All |
50 Years to 85 Years (Adult, Senior) |
NCT01399125 |
CENA713D2344 |
|
July 2011 |
May 2013 |
May 2013 |
July 21, 2011 |
August 4, 2014 |
August 4, 2014 |
- Novartis Investigative Site
Fuzhou, Fujian, China - Novartis Investigative Site
Wuhan, Hubei, China - Novartis Investigative Site
Wuhan, Hubei, China - (and 13 more...)
|
| 120 |
NCT00785759 |
Completed |
Brain Uptake and Safety With Probable Alzheimer's Disease, Amnestic Mild Cognitive Impairment and Healthy Volunteers |
- Alzheimer's Disease
- Amnestic Mild Cognitive Impairment
|
- Drug: AH110690 (18F) Injection
|
Interventional |
Phase 2 |
- GE Healthcare
- i3 Statprobe
- Medpace, Inc.
- Hvidovre Hospital Center Demark Danish Research Centre for Magnetic Resonance
|
Industry / Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Diagnostic
|
- Examine the efficacy and determine visual assessment of raised [18F] brain uptake for separating subjects with probable Alzheimer's Disease from healthy volunteers and assigning amnestic mild cognitive impairment cases to an AD or HV category.
- Examine the efficacy and parameters of brain [18F] uptake for separating 25 subjects with probable AD from 25 HV, assigning 20 amnestic MCI cases to an AD or HV category by measuring ranges of regional cerebral to cerebellum tracer uptake ratios.
|
78 |
All |
25 Years and older (Adult, Senior) |
NCT00785759 |
ALZ201 |
ALZ201 |
September 2008 |
March 2009 |
December 2009 |
November 5, 2008 |
December 7, 2009 |
|
- GE Healthcare
Oslo, Norway
|
| 121 |
NCT01908010 |
Completed |
Safety, Tolerability, and Pharmacokinetics of ABT-354 in Subjects With Mild-to-Moderate Alzheimer's Disease on Stable Doses of Acetylcholinesterase Inhibitors |
|
- Drug: ABT-354
- Drug: Placebo
|
Interventional |
Phase 1 |
|
Industry |
- Allocation: Randomized
- Intervention Model: Single Group Assignment
- Masking: Triple (Participant, Care Provider, Investigator)
- Primary Purpose: Treatment
|
- Vital signs
- ECG (electrocardiogram)
- Neurological exam
- (and 4 more...)
|
20 |
All |
55 Years to 90 Years (Adult, Senior) |
NCT01908010 |
M13-080 |
|
July 2013 |
November 2013 |
November 2013 |
July 25, 2013 |
December 11, 2013 |
|
- Site Reference ID/Investigator# 106999
Miami, Florida, United States - Site Reference ID/Investigator# 106998
Orlando, Florida, United States - Site Reference ID/Investigator# 107000
Overland Park, Kansas, United States
|
| 122 |
NCT02005380 |
Completed |
Usability Study of Spaced Retrieval Exercise Using Mobile Devices for Alzheimer's Disease Rehabilitation |
|
- Other: Text-based task
- Other: Graphic-based Task
|
Observational |
|
- German-Jordanian University
|
Other |
- Observational Model: Cohort
- Time Perspective: Cross-Sectional
|
- NASA Task Load Index Measure
- Test Score
|
20 |
All |
60 Years and older (Adult, Senior) |
NCT02005380 |
GJU001 |
|
November 2013 |
November 2013 |
November 2013 |
December 9, 2013 |
December 9, 2013 |
|
- Darat Samir Shamma
Amman, Jordan
|
| 123 |
NCT00731224 |
Completed |
Compliance and Tolerability of Rivastigmine Transdermal Patch 10 cm² in Patients With Probable Alzheimer's Disease. |
|
- Drug: Rivastigmine transdermal patch
|
Interventional |
Phase 4 |
- Novartis Pharmaceuticals
- Novartis
|
Industry |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Proportion of patients who can reach the target rivastigmine patch size of 10 cm2 and stay on it for at least 8 weeks.
- Mini-Mental State Examination (MMSE), Alzheimer's Disease Cooperative Study - Activities of Daily Living (ADCS-ADL), Global Deterioration Scale (GDS), caregiver burden (Zarit Burden Interview).
- Patient compliance (drug accounting)
|
380 |
All |
50 Years and older (Adult, Senior) |
NCT00731224 |
CENA713DAU01 |
CARE |
July 2008 |
October 2011 |
October 2011 |
August 8, 2008 |
March 28, 2017 |
|
- Novartis Investigative Site
East Gosford, New South Wales, Australia - Novartis Investigative Site
Gosford, New South Wales, Australia - Novartis Investigative Site
Hornsby, New South Wales, Australia - (and 37 more...)
|
| 124 |
NCT01524887 |
Terminated
Has Results |
Phase 3 IGIV, 10% in Alzheimer´s Disease |
|
- Biological: Immune Globulin Intravenous (Human), 10% Solution
- Biological: Human albumin 0.25%
|
Interventional |
Phase 3 |
- Baxalta now part of Shire
- Shire
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Double (Participant, Investigator)
- Primary Purpose: Treatment
|
- Change From Baseline to Month 18 in Cognitive Subscale of the Alzheimer´s Disease Assessment Scale (ADAS-Cog)
- Change From Baseline to Month 18 in Alzheimer´s Disease Cooperative Study (ADCS)-Activities of Daily Living (ADL) Inventory
- ADCS-Clinical Global Impression of Change (CGIC) at 18 Months
- (and 10 more...)
|
508 |
All |
50 Years to 89 Years (Adult, Senior) |
NCT01524887 |
161003
2011-000914-21 |
|
January 2012 |
July 2013 |
July 2013 |
February 2, 2012 |
November 24, 2017 |
March 31, 2015 |
- Birmingham, Alabama, United States
- Phoenix, Arizona, United States
- Long Beach, California, United States
- (and 66 more...)
|
| 125 |
NCT03117738 |
Recruiting |
A Study to Evaluate the Safety and Efficacy of AstroStem in Treatment of Alzheimer's Disease |
|
- Drug: AstroStem
- Other: Placebo-Control
|
Interventional |
Phase 1
Phase 2 |
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Triple (Participant, Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
|
- Treatment related adverse events
- ADAS-Cog (Alzheimer's Disease Assessment Scale-cognitive subscale)
- MMSE (Mini-mental status examination)
- (and 7 more...)
|
60 |
All |
50 Years and older (Adult, Senior) |
NCT03117738 |
AST-ADP2-US01 |
|
April 3, 2017 |
October 26, 2018 |
November 30, 2018 |
April 18, 2017 |
July 21, 2017 |
|
- ATP Clinical Research
Costa Mesa, California, United States - Syrentis Clinical Research
Santa Ana, California, United States - Valden Medical
Honolulu, Hawaii, United States
|
| 126 |
NCT01311492 |
Completed |
Exercise Trial for Alzheimer's Disease |
|
- Behavioral: Healthy Lifestyle Program
- Behavioral: Physical Activity Intervention
|
Interventional |
Not Applicable |
- Pennington Biomedical Research Center
- St. James Place of Baton Rouge
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Single (Investigator)
- Primary Purpose: Treatment
|
- Effect of exercise on cognitive decline
- Measuring the effects of exercise on depression, metabolic indices, and changes in overall function.
- Evidence based feasibility for conducting exercise interventions in the Alzheimer's Disease population.
|
10 |
All |
65 Years and older (Adult, Senior) |
NCT01311492 |
PBRC10035 |
EXTRA |
March 2011 |
April 2013 |
April 2013 |
March 9, 2011 |
May 27, 2013 |
|
- Programs of All-Inclusive Care for the Elderly (PACE)
Baton Rouge, Louisiana, United States - Pennington Biomedical Research Center
Baton Rouge, Louisiana, United States
|
| 127 |
NCT01527916 |
Completed |
Evaluate the Efficacy and Safety of ABT-126 in Subjects With Mild to Moderate Alzheimer's Disease |
|
- Drug: placebo
- Drug: donepezil
- Drug: ABT-126
|
Interventional |
Phase 2 |
- AbbVie (prior sponsor, Abbott)
- AbbVie
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Triple (Participant, Care Provider, Investigator)
- Primary Purpose: Treatment
|
- Alzheimer's Disease Assessment Scale - cognitive subscale
- Alzheimer's Disease Cooperative Study - Activities of Daily Living (ADCS-ADL)
- Mini Mental Status Exam (MMSE)
- (and 7 more...)
|
438 |
All |
55 Years to 90 Years (Adult, Senior) |
NCT01527916 |
M10-985
2011-002004-32 |
|
February 2012 |
November 2013 |
November 2013 |
February 7, 2012 |
November 19, 2014 |
|
- Site Reference ID/Investigator# 56503
Delray Beach, Florida, United States - Site Reference ID/Investigator# 56518
Tampa, Florida, United States - Site Reference ID/Investigator# 56514
West Palm Beach, Florida, United States - (and 30 more...)
|
| 128 |
NCT01703117 |
Recruiting |
Riluzole in Mild Alzheimer's Disease |
|
- Drug: Riluzole
- Drug: Placebo
|
Interventional |
Phase 2 |
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Double (Participant, Investigator)
- Primary Purpose: Treatment
|
- Imaging Biomarkers N-acetylaspartate (NAA) and FDG-PET values in regions of interest
- Cognitive function (neuropsychological tests); Glutamate levels obtained through MRS
|
48 |
All |
60 Years to 85 Years (Adult, Senior) |
NCT01703117 |
APE-0792 |
|
November 2013 |
November 2019 |
November 2019 |
October 10, 2012 |
September 25, 2017 |
|
- The Rockefeller University
New York, New York, United States
|
| 129 |
NCT01600469 |
Completed |
NMDA-enhancing Agent for Treatment of Mild Cognitive Impairment and Mild Alzheimer's Disease |
- Alzheimer's Disease
- Mild Cognitive Impairment
|
- Drug: DAOI-B
- Other: Placebo
|
Interventional |
Phase 2 |
- Chang Gung Memorial Hospital
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
|
- Change from baseline in Alzheimer's disease assessment scale-cognitive subscale in week 8, 16 and 24
- Change from baseline in Mini Mental Status Examination at week 8, 16 and 24
- Change from baseline in Instrumental Activities of Daily Living at week 8, 16 and 24
- (and 2 more...)
|
86 |
All |
50 Years to 90 Years (Adult, Senior) |
NCT01600469 |
99-2452A3 |
|
January 2012 |
May 2013 |
May 2013 |
May 17, 2012 |
June 4, 2013 |
|
- Kaohsiung Chang Gung Memorial Hospital
Kaohsiung, Taiwan
|
| 130 |
NCT01883648 |
Terminated |
Study to Evaluate Coconut Oil for Alzheimer's Disease |
|
- Drug: Coconut Oil Beverage
- Other: Placebo Beverage
|
Interventional |
Phase 2
Phase 3 |
- University of South Florida
|
Other |
- Allocation: Randomized
- Intervention Model: Crossover Assignment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
|
- Change from baseline to Month 3 of each treatment phase (a 3 month period of time) in cognitive testing (ADAS-cog, MMSE, Category/Letter Fluency)
- Change from baseline to Month 3 of each treatment phase (a 3 month period of time) in Trails A & B cognitive testing
- Change from baseline to Month 3 of each treatment phase (a 3 month period of time) on Geriatric Depression Scale
- (and 4 more...)
|
21 |
All |
55 Years to 90 Years (Adult, Senior) |
NCT01883648 |
Byrd AD-001 |
|
June 2013 |
February 1, 2017 |
February 1, 2017 |
June 21, 2013 |
April 28, 2017 |
|
- USF Health Byrd Alzheimer's Institute
Tampa, Florida, United States
|
| 131 |
NCT01251718 |
Completed |
Post-marketing Surveillance of Donepezil Hydrochloride -Investigation of the Clinical Safety and Effectiveness in Patients With Alzheimer's Disease |
|
- Drug: donepezil hydrochloride
|
Observational |
|
- Eisai Co., Ltd.
- Eisai Inc.
|
Industry |
- Observational Model: Cohort
- Time Perspective: Prospective
|
- ADAS-Jcog (test of cognitive function)
- Adverse events/adverse drug reactions
|
894 |
All |
Child, Adult, Senior |
NCT01251718 |
ART06T |
|
December 1, 2010 |
October 14, 2015 |
February 18, 2016 |
December 2, 2010 |
February 27, 2017 |
|
- Anjo, Aichi, Japan
- Nagoya, Aichi, Japan
- Daisen, Akita, Japan
- (and 103 more...)
|
| 132 |
NCT03186989 |
Recruiting |
Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of IONIS-MAPTRx in Patients With Mild Alzheimer's Disease |
|
- Drug: IONIS MAPTRx
- Other: Placebo
|
Interventional |
Phase 1
Phase 2 |
- Ionis Pharmaceuticals, Inc.
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Double (Participant, Investigator)
- Primary Purpose: Other
|
- Incidence and severity of adverse events that are related to treatment with IONIS MAPTRx
- Pharmacokinetics (PK) after ascending dose-levels of multiple IT bolus administrations of IONIS MAPTRx (trough concentration)
- Pharmacokinetics (PK) after ascending dose-levels of multiple IT bolus administrations of IONIS MAPTRx (maximum observed drug concentration or Cmax)
- (and 3 more...)
|
44 |
All |
50 Years to 74 Years (Adult, Senior) |
NCT03186989 |
ISIS 814907-CS1 |
|
June 5, 2017 |
January 31, 2020 |
February 29, 2020 |
June 14, 2017 |
February 21, 2018 |
|
- Montreal Neurological Hospital
Montréal, Canada - Clinical Research Services Turku CRST
Turku, Finland - Charite - Universitaetsmedizin Berlin Campus Mitte
Berlin, Germany - (and 9 more...)
|
| 133 |
NCT00357357 |
Completed |
European Study of HF0220 in Mild to Moderate Alzheimer's Disease Patients |
|
|
Interventional |
Phase 2 |
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Triple (Participant, Care Provider, Investigator)
- Primary Purpose: Treatment
|
- Safety/tolerability of HF 0220 in mild to moderate Alzheimer's patients
- Validate biochemical markers relevant to Alzheimer's disease
- Assess the suitability of chosen HF0220 dose levels for future studies
|
40 |
All |
55 Years and older (Adult, Senior) |
NCT00357357 |
HF0220/003
2005-005791-32 |
|
July 2006 |
August 2008 |
August 2008 |
July 27, 2006 |
August 21, 2008 |
|
- King George Hospital
Visakhapatnam, Andh Prad, India - Manipal Hospital,
Bangalore, Karna, India - Sree Chitra Tirunal Institute for Medical Sciences and Technology
Thiruvananthapuram, Kerala, India - (and 7 more...)
|
| 134 |
NCT00678431 |
Completed |
Randomized Trial of a Nutritional Supplement in Alzheimer's Disease |
|
- Dietary Supplement: Resveratrol with Glucose, and Malate
- Dietary Supplement: Placebo
|
Interventional |
Phase 3 |
- VA Office of Research and Development
- Alzheimer's Association
- Icahn School of Medicine at Mount Sinai
|
U.S. Fed / Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
|
- Alzheimer Disease Assessment Scale (ADAScog)
- CGIC
|
27 |
All |
50 Years to 90 Years (Adult, Senior) |
NCT00678431 |
0553-06-071 |
|
January 2008 |
December 2010 |
June 2011 |
May 15, 2008 |
November 15, 2012 |
|
- James J. Peters VA Medical Center, Bronx, NY
Bronx, New York, United States
|
| 135 |
NCT03112096 |
Recruiting |
A Phase I [18F]THK-5351 Positron Emission Tomography Study in Healthy Subjects and Alzheimer's Disease |
|
|
Interventional |
Phase 1 |
|
Other |
- Allocation: Non-Randomized
- Intervention Model: Parallel Assignment
- Masking: Single (Investigator)
- Primary Purpose: Diagnostic
|
- Pharmacokinetics: Maximum Serum Concentration (Cmax) of [18F]THK-5351
- Assess global and regional tau deposition as measured by standard uptake value ratio (SUVR) of [18F]THK-5351
- Correlation between standard uptake value ratio (SUVR) and distribution volume of ratio(DVR) of [18F]THK-5351 positron emission computed tomography
- (and 3 more...)
|
20 |
All |
20 Years to 80 Years (Adult, Senior) |
NCT03112096 |
THK-15001 |
|
May 17, 2017 |
August 30, 2018 |
August 30, 2018 |
April 13, 2017 |
May 18, 2017 |
|
- Asan Medical Center
Seoul, Korea, Republic of
|
| 136 |
NCT01549834 |
Completed |
Evaluate the Efficacy and Safety of ABT-126 in Subjects With Mild to Moderate Alzheimer's Disease on Stable Doses of Acetylcholinesterase Inhibitors |
|
- Drug: ABT-126
- Drug: placebo
|
Interventional |
Phase 2 |
- AbbVie (prior sponsor, Abbott)
- AbbVie
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Triple (Participant, Care Provider, Investigator)
- Primary Purpose: Treatment
|
- Alzheimer's Disease Assessment Scale - cognitive subscale
- Mini Mental Status Exam
- Alzheimer's Disease Cooperative Study - Activities of Daily Living (ADCS-ADL)
- (and 7 more...)
|
434 |
All |
55 Years to 90 Years (Adult, Senior) |
NCT01549834 |
M11-793
2011-004849-40 |
|
March 2012 |
October 2013 |
October 2013 |
March 9, 2012 |
October 31, 2014 |
|
- Site Reference ID/Investigator# 66528
Fresno, California, United States - Site Reference ID/Investigator# 69602
Long Beach, California, United States - Site Reference ID/Investigator# 66527
San Francisco, California, United States - (and 40 more...)
|
| 137 |
NCT01075763 |
Completed
Has Results |
A Pilot Trial of Interferon Beta-1a in Alzheimer's Disease |
|
- Drug: Interferon beta-1a
- Drug: Placebo
|
Interventional |
Phase 2 |
- Merck KGaA
- Merck Serono S.P.A., Italy
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Double (Participant, Investigator)
- Primary Purpose: Treatment
|
- Alzheimer's Disease Assessment Scale, Cognitive Subscale (ADAS-Cog) Score
- Mini Mental Status Examination (MMSE) Score
- Alzheimer's Disease Assessment Scale, Non-cognitive Subscale (ADAS-NonCog) Score
- (and 5 more...)
|
42 |
All |
50 Years to 75 Years (Adult, Senior) |
NCT01075763 |
24386 |
REAL |
November 2004 |
May 2008 |
May 2008 |
February 25, 2010 |
February 13, 2014 |
April 4, 2012 |
- U.VA. Neurologia - Azienda Ospedaliera Garibaldi Nesina
Catania, CT, Italy
|
| 138 |
NCT02886494 |
Recruiting |
A Study to Evaluate Efficacy and Safety of BAC in Patient With Alzheimer's Disease or Vascular Dementia |
- Alzheimer's Disease or Vascular Dementia
|
- Drug: BAC
- Drug: Matched placebo
|
Interventional |
Phase 2 |
- Charsire Biotechnology Corp.
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Triple (Participant, Care Provider, Investigator)
- Primary Purpose: Treatment
|
- Change in Alzheimer Disease Assessment Scale-cognitive (ADAS-cog) score at Week 12 visit compared to baseline
- Change in ADAS-cog score at all post treatment visits (except Week 12 visit) compared to baseline
- Clinician's Interview Based Impression of Change-Plus Caregiver Input (CIBIC-plus) score at all post treatment visits
- (and 4 more...)
|
60 |
All |
40 Years and older (Adult, Senior) |
NCT02886494 |
BAC-02 |
|
December 2016 |
November 2018 |
November 2019 |
September 1, 2016 |
March 9, 2018 |
|
- Clinical Research Consortium
Tempe, Arizona, United States - Woodland International Research Group
Little Rock, Arkansas, United States - Woodland Research Northwest, LLC
Rogers, Arkansas, United States - (and 7 more...)
|
| 139 |
NCT01876459 |
Unknown † |
Alpha-synuclein in Cerebrospinal Fluid to Differentiate Alzheimer's Disease From Lewy Body Disease. |
- "Alzheimer's Disease" and "Lewy Body Disease"
|
- Other: MRI
- Procedure: lumbar puncture
- Behavioral: neuropsychological tests
|
Interventional |
Not Applicable |
- University Hospital, Strasbourg, France
|
Other |
- Allocation: Non-Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Diagnostic
|
- rate of alpha-synuclein in cerebrospinal fluid
|
265 |
All |
45 Years and older (Adult, Senior) |
NCT01876459 |
5330
N° IDRCB 2012-A00992-41 |
AlphaLewyMa |
April 2013 |
April 2015 |
April 2015 |
June 12, 2013 |
June 18, 2013 |
|
- Hôpitaux Universitaires de Strasbourg
Strasbourg, Hôpital de Hautepierre, France
|
| 140 |
NCT03352557 |
Recruiting |
Phase 2 Study of BIIB092 in Participants With Early Alzheimer's Disease |
|
- Drug: BIIB092
- Drug: Placebo
|
Interventional |
Phase 2 |
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
|
- Percentage of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)
- Percentage of Participants With Abnormal Laboratory Safety Assessments
- Percentage of Participants With Changes From Baseline Over Time in Laboratory Safety Assessments
- (and 7 more...)
|
528 |
All |
50 Years to 80 Years (Adult, Senior) |
NCT03352557 |
251AD201
2017-002901-37 |
TANGO |
April 20, 2018 |
July 21, 2021 |
September 8, 2021 |
November 24, 2017 |
April 11, 2018 |
|
- Xenoscience Inc
Phoenix, Arizona, United States - Associated Neurologists of Southern Connecticut, P.C.
Fairfield, Connecticut, United States - JEM Research Institute
Atlantis, Florida, United States - (and 3 more...)
|
| 141 |
NCT00684944 |
Completed |
Open Label Study of TRx0014 in Alzheimer's Disease |
|
|
Interventional |
Phase 2 |
|
Industry |
- Allocation: Non-Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Cognitive ability measured by the Alzheimer's Disease Assessment Scale - cognitive subscale (ADAS-cog) and by the Mini-Mental State Examination (MMSE).
- Dementia severity assessed by the Clinical Dementia Rating - sum of the boxes (CDR-sb).
- Daily living activities assessed by the Alzheimer's Disease functional Assessment and Change Scale (ADFACS)
|
111 |
All |
Child, Adult, Senior |
NCT00684944 |
TRx-014-009 |
|
July 2007 |
December 2010 |
December 2011 |
May 28, 2008 |
February 2, 2012 |
|
|
| 142 |
NCT00480220 |
Completed |
Specific Care and Assistance Plan for Alzheimer's Disease |
|
- Procedure: Global care and support program
|
Interventional |
Not Applicable |
- University Hospital, Toulouse
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Supportive Care
|
- Evaluate the efficacy of the specific care and assistance plan for Alzheimer's disease in a study randomised within each centre. The main aim of the care plan is to reduce loss of independence.
- Impact of the care and assistance plan: - on the mode of the patient's admission to an institution - on utilization of assistance, support and healthcare services (RUD questionnaire) - and on overall clinical evaluation of change (ADCS-CGIC).
|
1200 |
All |
65 Years and older (Adult, Senior) |
NCT00480220 |
0200601
PHRC |
PLASA |
August 2003 |
August 2007 |
August 2007 |
May 30, 2007 |
August 19, 2015 |
|
- Hospital
Albi, France - Hospital Center
Ales, France - University Hospital
Angers, France - (and 37 more...)
|
| 143 |
NCT00088673 |
Unknown † |
Evaluation of 3APS in Patients With Mild to Moderate Alzheimer’s Disease |
|
|
Interventional |
Phase 3 |
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Double
- Primary Purpose: Treatment
|
- The two primary efficacy parameters are the change from baseline to month 18 in the Alzheimer's Disease Assessment Scale, cognitive subpart (ADAS-cog) and the clinical Deterioration Scale Sum of Boxes (CDR-SB) scores.
- The brain volume change from baseline as measured by Magnetic Resonance Imaging will also be assessed.
|
950 |
All |
50 Years and older (Adult, Senior) |
NCT00088673 |
CL-758007 |
|
June 2004 |
|
|
August 3, 2004 |
February 28, 2007 |
|
- Pivotal Research Centers
Peoria, Arizona, United States - 21st Century Neurology, a division of Xenoscience
Phoenix, Arizona, United States - Central Arkansas Research
Hot Springs, Arkansas, United States - (and 64 more...)
|
| 144 |
NCT01078168 |
Completed
Has Results |
Alzheimer`s Disease Acitretin Medication |
|
- Drug: Acitretin
- Drug: Placebo
|
Interventional |
Phase 2 |
- K. Lieb
- Alzheimer Forschungsinitiative e.V. (AFI)
- Johannes Gutenberg University Mainz
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Double (Participant, Investigator)
- Primary Purpose: Treatment
|
- Difference in Cerebrospinal Fluid (CSF) Soluble Alpha-clevaed Amyloid Precursor Protein (APPsα) Concentration at Visit 3 Compared to Baseline
|
22 |
All |
18 Years and older (Adult, Senior) |
NCT01078168 |
ADAM
2009-011881-27 |
ADAM |
March 2010 |
January 2013 |
May 2013 |
March 2, 2010 |
February 2, 2018 |
February 2, 2018 |
- Department of psychiatry and psychotherapy, University medical center of the Johannes Gutenberg-University Mainz
Mainz, Rheinland-Pfalz, Germany - Universität Rostock
Rostock, Germany
|
| 145 |
NCT01948791 |
Completed
Has Results |
16w Interventional Study on Titration and Dose/Efficacy Assessment of Exelon in Chinese Alzheimer's Disease Patients |
|
|
Interventional |
Phase 4 |
- Novartis Pharmaceuticals
- Novartis
|
Industry |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Mean Change From Baseline in the Alzheimer's Disease Assessment Scale - Cognitive Subscale (ADAS-cog)
- Change From Baseline in the Alzheimer's Disease Cooperative Study-Activities of Daily Living (ADCS-ADL) Score
- Change From Baseline in Mini-Mental State Examination (MMSE)
- (and 2 more...)
|
222 |
All |
50 Years to 85 Years (Adult, Senior) |
NCT01948791 |
CENA713BCN05 |
INSTINCT |
August 2014 |
September 2015 |
September 2015 |
September 24, 2013 |
February 13, 2017 |
February 13, 2017 |
- Novartis Investigative Site
Beijing, China
|
| 146 |
NCT01018875 |
Completed |
Efficacy and Safety Study of ABT-288 in Subjects With Mild-to-Moderate Alzheimer's Disease |
|
- Drug: ABT-288
- Drug: donepezil
- Drug: placebo
|
Interventional |
Phase 2 |
- AbbVie (prior sponsor, Abbott)
- AbbVie
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
|
- ADAS-cog: Alzheimer's Disease Assessment Scale - Cognition portion
- MMSE: Mini Mental Status Exam
- NPI: Neuropsychiatric Inventory
- (and 2 more...)
|
242 |
All |
55 Years to 90 Years (Adult, Senior) |
NCT01018875 |
M10-822
2009-010704-29 |
|
December 2009 |
February 2011 |
February 2011 |
November 24, 2009 |
January 29, 2013 |
|
- Site Reference ID/Investigator# 22687
Kazan, Russian Federation - Site Reference ID/Investigator# 22636
Moscow, Russian Federation - Site Reference ID/Investigator# 23702
Moscow, Russian Federation - (and 18 more...)
|
| 147 |
NCT01137526 |
Completed |
Efficacy and Safety Study of ABT-384 in Subjects With Mild-to-Moderate Alzheimer's Disease |
|
- Drug: ABT-384
- Drug: donepezil
- Drug: placebo
|
Interventional |
Phase 2 |
- AbbVie (prior sponsor, Abbott)
- AbbVie
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Triple (Participant, Care Provider, Investigator)
- Primary Purpose: Treatment
|
- Change from baseline to final observation in the Alzheimer's Disease Assessment Scale-Cognition portion (ADAS-cog) total score
- Mini Mental Status Examination (MMSE) score at Baseline, Weeks 4, 8, and 12
- Clinician's Interview Based Impression of Change-plus (CIBIC-plus) score at Baseline, Weeks 4, 8, and 12
- (and 2 more...)
|
267 |
All |
55 Years to 90 Years (Adult, Senior) |
NCT01137526 |
M12-033
2009 017801-12 |
|
May 2010 |
July 2011 |
July 2011 |
June 4, 2010 |
January 29, 2013 |
|
- Site Reference ID/Investigator# 40834
Ekaterinburg, Russian Federation - Site Reference ID/Investigator# 36304
Kazan, Russian Federation - Site Reference ID/Investigator# 36306
Kirov, Russian Federation - (and 27 more...)
|
| 148 |
NCT02195596 |
Unknown † |
Effects of Exercise on Cognitive Performance of Patients With Alzheimer-type Dementia. Pilot Study. |
|
- Other: High intensity aerobic exercise+strength
- Other: Low intensity aerobic exercise+strength
|
Interventional |
Not Applicable |
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Single (Investigator)
- Primary Purpose: Supportive Care
|
- Change in cognitive performance that is measured in a blinded way with the cognitive section of the ADAS scale (Alzheimer's Disease Assessment Scale) at 0, 6 and 12
- Global cognitive performance
|
80 |
All |
55 Years to 85 Years (Adult, Senior) |
NCT02195596 |
2011111100 |
EFA-P |
April 2013 |
January 2015 |
December 2015 |
July 21, 2014 |
July 21, 2014 |
|
- Galdakao Hospital/Galdakao C.S.
Galdakao, Bilbao, Spain - Basauri C.S.
Basauri, Bizkaia, Spain - Hospital Universitario de Basurto
Bilbao, Bizkaia, Spain
|
| 149 |
NCT01677754 |
Completed |
A Study of RO4602522 in Participants With Moderate Severity Alzheimer Disease on Background Alzheimer Disease Therapy |
|
- Drug: RO4602522
- Drug: Placebo
- Drug: Donepezil
- (and 3 more...)
|
Interventional |
Phase 2 |
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Double (Participant, Investigator)
- Primary Purpose: Treatment
|
- Change From Baseline in Alzheimer's Disease Assessment Scale - Cognitive Behavior Subscale (ADAS-Cog-11) Score at Month 12
- Percentage of Participants Achieving Response, Defined as an Increase From Baseline of Less Than or Equal to (<=) 4 Points in ADAS-Cog-11
- Change From Baseline in Alzheimer's Disease Cooperative Study - Activities of Daily Living (ADCS-ADL) Scale Score at Month 12
- (and 16 more...)
|
542 |
All |
50 Years to 90 Years (Adult, Senior) |
NCT01677754 |
BP28248
2012-000943-29 |
MAyflOwer RoAD |
October 24, 2012 |
June 12, 2015 |
June 12, 2015 |
September 3, 2012 |
May 30, 2017 |
|
- Advanced Research Center, Inc.;In-Patient Unit
Anaheim, California, United States - Neurology Center of North Orange County
Fullerton, California, United States - Torrance Clinical Research
Lomita, California, United States - (and 139 more...)
|
| 150 |
NCT02864303 |
Recruiting |
Use of Saliva for Alzheimer's Disease Diagnosis |
- Alzheimer's Disease
- Mild Cognitive Impairment
|
|
Interventional |
Not Applicable |
- University Hospital, Montpellier
|
Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
|
- Aβ40 and Aβ42
- Neuropsychologic tests
- ApoE polymorphism
|
250 |
All |
55 Years to 80 Years (Adult, Senior) |
NCT02864303 |
8835 |
SalivALZ |
June 2012 |
December 2018 |
December 2018 |
August 12, 2016 |
December 22, 2016 |
|
|
Create an RSS feed from your search for:
Download the search results for: